Free Trial
NASDAQ:INBX

Inhibrx Biosciences Q4 2024 Earnings Report

Inhibrx Biosciences logo
$14.91 +0.15 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$15.01 +0.10 (+0.64%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx Biosciences EPS Results

Actual EPS
-$2.80
Consensus EPS
-$2.55
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

Inhibrx Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibrx Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Inhibrx Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Inhibrx Biosciences Earnings Headlines

Inhibrx Biosciences Inc (INBX) - Investing.com
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Inhibrx Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx Biosciences and other key companies, straight to your email.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

View Inhibrx Biosciences Profile

More Earnings Resources from MarketBeat